Biota

biota pharmaceuticals is focused on the discovery and development of direct-acting antivirals to treat infections that affect a significant number of patients globally. the company has four product candidates in development that address viral infections that have limited therapeutic options. we are currently enrolling patients for the phase 2b spiritus trial for vapendavir, a potent, broad spectrum capsid inhibitor of enteroviruses, for the treatment of human rhinovirus (hrv) infected patients with moderate-to-severe asthma. our second phase 2 clinical product candidate is bta074 (ap611074), a novel topical treatment for genital warts caused by hpv types 6 & 11. we also are developing bta-c585, an oral fusion inhibitor in development for the treatment of respiratory syncytial virus infections. we anticipate beginning a phase 1 clinical trial with bta-c585 in q3 2105. laninamivir octanoate, a one-time, inhaled neuraminidase for the treatment of influenza a and b infections has complet